Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

On The Trail Of Biosimilar Disclosure Scofflaws: FTC To Watch For Anti-Competitive Issues

May 07 2012

• By Derrick Gingery

Related Content

FDA Meetings With Biosimilar Sponsors Aim To Make 351(k) Pathway OK

Dec 16 2011

FDA Enforcement Powers Remain In Limbo As User Fee Bill Glides Through Markup

Apr 26 2012

User Fee Legislation Revs Through Senate Mark-up, But House Bill Goes Back Into The Shop

Apr 30 2012

Biosimilars Pathway Has Blind Spots As FDA And Firms Begin Roadwork

May 03 2010

FDA Searches For Clinical Trial Middle Ground At Biosimilar Hearing

Nov 08 2010

Biosimilars Should Face Patent Challenges Only After Approval, Novartis Says

Oct 27 2008

Related Companies

Novartis AG

Additional Topics

United States Legal Issues Regulation BioPharmaceutical

More from United States

More from North America

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window